Irhythm Technologies: A Strong Buy on Solid Growth Trajectory and Innovative Developments

Wells Fargo analyst Nathan Treybeck has maintained their bullish stance on IRTC stock, giving a Buy rating on May 6.

Nathan Treybeck has given his Buy rating due to a combination of factors that highlight Irhythm Technologies’ growing market presence and innovative product developments. One of the key reasons is the increasing volume and strong pipeline driven by the Zio Monitor, Camelot data, and primary care physician (PCP) expansion. In the first quarter, the company matched its previous record for new account openings and reported near all-time high average volume per new account, with many of these being competitive conversions. Additionally, Irhythm has successfully regained market share in the last 6-7 months, which demonstrates competitive strength and market acceptance of their products.

Furthermore, the anticipation of new product launches such as the Zio MCT, which is expected to be introduced in the second half of 2025, has the potential to significantly increase revenue. The management’s confidence in resolving the FDA warning letter by the end of the first quarter of 2025, the comfort with new design features of Zio AT, and the unforeseen rise of a Know Your Rhythm partner to a top prescriber status, which has not yet been factored into guidance, all present upside potential. The full launch of Signify in the second half of the year could add a substantial revenue stream, with expectations set high due to early successful outcomes. These developments suggest that Irhythm Technologies is on a solid growth trajectory, justifying the Buy rating that Nathan Treybeck has assigned.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Irhythm Technologies (IRTC) Company Description:

iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.